Speratum is a biotechnology company developing innovative, targeted molecular therapies or the treatment of cancer. We combine the latest advances in synthetic biology with a revolutionary drug delivery system, originally developed at Baylor College of Medicine and licensed exclusively to Speratum.
The company was founded in 2014 by the co-inventor of its core technologies, Dr. Christian Marín-Müller through a partnership with Carao Ventures, the leading technology investment firm and start up accelerator in the region. Since then, the company has expanded its patent portafolio to transform the technology from a single focus therapeutic to a flexible, reprogrammable molecular scaffold, fully adaptable to a variety oligonucleotide-based therapeutics.
We are currently completing a pre-clinical development of our novel therapeutic platform, testing efficacy and safety in animal models, and plan to take our first product to the clinic within the next 12-18 months.
If you would like to have more information about our technology, please contact us with our Contact Us form.
For career opportunities and general inquiries, please contact us with the following form: